Format

Send to

Choose Destination
See comment in PubMed Commons below
Mov Disord. 2014 Apr;29(4):562-6. doi: 10.1002/mds.25777. Epub 2013 Dec 27.

Nizatidine ameliorates gastroparesis in Parkinson's disease: a pilot study.

Author information

1
Pharmaceutical Unit, Sakura Medical Center, Toho University, Sakura, Japan.

Abstract

BACKGROUND:

The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.

METHODS:

Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.

RESULTS:

NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax ((13) C) (the peak time of the (13) C-dose-excess curve) (P < 0.05).

CONCLUSIONS:

Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients.

KEYWORDS:

Parkinson's disease; gastric emptying; gastroparesis; levodopa; nizatidine

PMID:
24375669
DOI:
10.1002/mds.25777
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center